Biostage, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BSTG research report →
About the company
Biostage, Inc. is a biotechnology enterprise dedicated to developing medical products aimed at curing patients suffering from cancers, injuries, and congenital defects within the gastrointestinal system and respiratory pathways. A primary focus for the company is the advancement of its Biostage Esophageal Implant, specifically designed to address esophageal cancer.
- CEO
- Junli He
- IPO
- 2013
- Employees
- 7
- HQ
- Holliston, MA, US
Price Chart
- Market Cap
- $57.82M
- P/E
- -2.53
- P/S
- 41.09
- P/B
- 198.74
- EV/EBITDA
- -2.69
- Div Yield
- 0.00%
- Gross Margin
- -84.04%
- Op Margin
- -1689.21%
- Net Margin
- -1530.56%
- ROE
- -786.49%
- ROIC
- -2836.60%
- Revenue
- $0 · 0.00%
- Net Income
- $-6,869,000 · 11.16%
- EPS
- $-0.42 · 19.23%
- Op Income
- $-7,619,000
- FCF YoY
- 21.10%
- 52W High
- $9.00
- 52W Low
- $3.65
- 50D MA
- $4.75
- 200D MA
- $5.89
- Beta
- -0.97
- Avg Volume
- 972
Get TickerSpark's AI analysis on BSTG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BSTG coverage
Recent articles, reports, and earnings notes.
No research on BSTG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BSTG report →Similar companies
Peers in the same neighborhood.